CK Life Sciences Plummets Over 4% Amid Widened Annual Loss and Surging R&D Costs
Stock News
Mar 20
CK Life Sciences (00775) has declined more than 4%, bringing its cumulative loss for the month to nearly 15%. As of the latest update, the stock fell 4% to HK$0.72, with a turnover of HK$5.93 million. The company released its annual results, reporting revenue of HK$5.41 billion, down 2% year-on-year. The loss attributable to shareholders widened to HK$187 million, an increase of 47.61% compared to the previous year. According to the announcement, the increased loss of HK$60.2 million in the 2025 fiscal year compared to 2024 reflects a rise in research and development expenses of HK$66.5 million, along with several non-recurring and one-time items.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.